NFE2L2 and liver cancer: At the same time, however, there were instances of luteolin acting as an NRF2 activator, inducing the NRF2/ARE pathway and causing higher expression of said pathways’ downstream genes; for example, in human liver cancer HepG2 cells, increased mRNA and protein levels of NRF2 and HO-1 were observed [9,30,32].